Navigation Links
New Study Questions Ability of Radiology Benefit Managers to Lower Costs
Date:6/1/2011

ies delegate to their staffs the collection and communication of the information the RBM requires, and the study calculates the time and cost involved in responding to and addressing the requests. For a population of 100,000 insured individuals, the study estimates that RBMs shift costs of $182,066 onto physicians and their staffs. When scaled up to the approximately 88 million Americans currently covered by private health plans with RBMs, the model suggests 28 percent  of the projected RBM-related savings are shifted to providers, costing them approximately $160 million per year.  Indirect costs associated with RBM actions include decreased productivity resulting from diagnosis without imaging, delays in the provision of needed imaging services and disease progression that could have been prevented or delayed by using diagnostic imaging to determine an appropriate patient treatment course.

While Lee states, "Our conclusion that RBMs may increase rather than decrease cost is based on parameter values used in a simulation model that have not yet been substantiated," he notes there is a growing body of evidence that prior-authorization programs for drugs and other health care services are associated with both cost shifting and added costs to the health care system overall.  Specific to Medicare, Lee contends that an RBM prior authorization program would also likely result in a cost shift to private payers, as Medicare has fixed rates.

Clinical decision support tools, the study's authors contend, are one option for reducing cost shifting caused by RBMs. Similar to RBMs, they provide feedback on the appropriateness of the imaging study being ordered.  Unlike RBMs, decision support tools do not approve or deny requests; rather they provide appropriateness information electronically and on a real-time basis.

Commenting on the Lee, Rawson, Wade RBM study, Liz Quam, the co-founder of the Imaging e-Ordering Coalition, which represents
'/>"/>

SOURCE GE Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
2. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
3. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
4. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
5. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
6. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
7. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
8. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
9. U-M Study: Children Dependent on Long-Term Mechanical Ventilation Require Longer, More Expensive Hospital Care
10. Use of TIGR® Matrix Surgical Mesh in Multi-Center Randomized Controlled TRAM Flap Study Passes 20 Patient Mark and Wins Praise from Participating Surgeons
11. Study Finds Long-Term Treatment with TRIBENZOR™ was Effective and Well-Tolerated Regardless of Age, Race, or Diabetes Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... May 21, 2007/PRNewswire-FirstCall/ -- Bristol-Myers,Squibb Company (NYSE: ... which showed that treatment with Baraclude (entecavir),demonstrated ... 48 weeks,-- a result that was also ... These data from an open-label, randomized viral ...
... -- Data presented,today at a major medical meeting ... for five days is as,effective as standard therapy ... treatment of complicated urinary tract infections,(cUTI) and acute ... markets LEVAQUIN in the,U.S., presented the data during ...
Cached Medicine Technology:Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4
(Date:12/21/2014)... December 21, 2014 Serious Buyer, Andrew ... 1967 Jm Morrison and the Doors International Ballroom at ... would also be the only time that Morrison's mother ... on Nov. 25, 1967. According to Hawley, “This would ... did play the Alexandria Roller Rink earlier that year ...
(Date:12/21/2014)... Columbus, OH (PRWEB) December 21, 2014 ... of men alleging heart attacks, stroke and blood clots ... continue to increase, a new study shows that the ... developing colon cancer. In a study published in the ... lead researcher, James Amos-Landgraf examined a group of male ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is ... the business has announced its bamboo flooring promotion ... best material from certified suppliers, and offers the ... worldwide. In the current promotion, all customers can ... when they say they know BambooIndustry.com from press ...
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... ) that allege a metal-on-metal version of the ... move forward in state and federal courts, Bernstein ... in New Jersey’ Bergen County Superior Court on ... were permitted to begin deposition of plaintiffs on ...
(Date:12/20/2014)... 20, 2014 Angeldress.co.uk, the distinguished wedding ... for worldwide dress fans. The company has recently updated ... information. For the holiday season, Angeldress Blog ... wedding apparel. , Angeldress.co.uk prides itself in offering a ... of service. All the company’s outfits are very carefully ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2
... Oct. 24 (HealthDay News) -- Roughly 10 percent of Americans ... that doing so increases their risk for three common skin ... In conducting the study, researchers tracked the tanning bed ... high school and college, and then when the women were ...
... team led by scientists from The University of Texas MD ... their quest to map the vast blood vessel network of ... of Oct. 24 in the Proceedings of the National ... the goal of using the vascular system to personalize cancer ...
... Furlong founded Parent Project Muscular Dystrophy (PPMD) in 1995 to ... dystrophy with both resources and hope. Now, Furlong has blazed ... She has spearheaded a partnership between PPMD and the Public ... Currents: Muscular Dystrophy, this month. The story of the partnership ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, Oct. 24 ... the airways of children with autism that she says may ... While examining children with autism who came in for a ... can see down into the windpipe and the airways that ...
... related macular degeneration (AMD) is the leading cause of ... identified several relatively common genetic variants which together predict ... number of persons without the disease also have these ... able to clearly show a specific rare mutation called ...
... University,s Office of Intellectual Property and Commercialization and ... institution,s faculty and researchers for technologies they have ... inventors. Faculty recognized for these achievements represent ... of Applied and Natural Sciences, College of Liberal ...
Cached Medicine News:Health News:More Evidence Links Tanning Beds to Higher Skin Cancer Risk 2Health News:Blood vessel mapping reveals 4 new 'ZIP codes' 2Health News:Blood vessel mapping reveals 4 new 'ZIP codes' 3Health News:Patient advocacy groups turn to open-access publishing to advance research quest 2Health News:Could Airway Abnormality Point to Autism? 2Health News:Could Airway Abnormality Point to Autism? 3Health News:Researchers ID genetic mutation associated with high risk of age-related macular degeneration 2Health News:Louisiana Tech University recognizes innovators, inventors 2Health News:Louisiana Tech University recognizes innovators, inventors 3
... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
... The PACHETT 3 uses the exact enhanced ... the DGH pachymeters used exclusively by the ... built into the software. The new backlit ... running average, standard deviation and IOP correction ...
... Already, the most advanced motor driven ... easier and faster to learn and operate. ... maintaining accuracy and precision. Our software makes ... easy transition from manual instruments or other ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
Medicine Products: